MedTrace Logo

To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients

NCT01768468 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2013-10-14

No results posted yet for this study

Summary

This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet and Joins tablet in the treatment of osteoarthritis of the knee.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

LAYLA tablet

1 tablet twice a day

DRUG

JOINS tablet

1 tablet at each time, 3 times a day

Sponsors & Collaborators

  • PMG Pharm Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ye Soo Park · Hanyang University

  • Chul Won Ha · Samsung Medical Center

  • Ye Yeon Won · Ajou University School of Medicine

  • Jae Hyup Lee · SMG-SNU Boramae Medical Center

  • Byung Woo Min · Keimyug University Dongsan Medical Center

  • Seung Beom Han · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-06-30
Completion
2013-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768468 on ClinicalTrials.gov